Nor­we­gian biotech con­cludes 's­trate­gic' re­view with a re­verse merg­er

A lit­tle Nor­we­gian biotech an­nounced the end of its jour­ney Thurs­day in a re­verse merg­er, rough­ly three months af­ter an­nounc­ing it would es­sen­tial­ly sell it­self …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER